Effect of Antenatal Betamethasone Use on Adrenal Gland Size and Endogenous Cortisol and 17-Hydroxyprogesterone in Preterm Neonates

Basit Öğe Kaydı
dc.contributor.authorBuyukkayhan, Derya
dc.contributor.authorOzturk, Mehmet Adnan
dc.contributor.authorKurtoglu, Selim
dc.contributor.authorKoklu, Esad
dc.contributor.authorYikilmaz, Ali
dc.date.accessioned2019-07-27T12:10:23Z
dc.date.accessioned2019-07-28T10:14:00Z
dc.date.available2019-07-27T12:10:23Z
dc.date.available2019-07-28T10:14:00Z
dc.date.issued2009
dc.department[Buyukkayhan, Derya] Cumhuriyet Univ, Sch Med, Dept Neonatol, TR-58140 Sivas, Turkey -- [Ozturk, Mehmet Adnan -- Kurtoglu, Selim -- Koklu, Esad] Erciyes Univ, Sch Med, Dept Neonatol, Kayseri, Turkey -- [Yikilmaz, Ali] Erciyes Univ, Sch Med, Dept Radiol, Kayseri, Turkeyen_US
dc.description.abstractAim: To assess the effect of antenatal betamethasone use on adrenal gland size and adrenal hormones in preterm neonates who had gestational ages of 27-36 weeks. Infants and Methods: Sixty-six neonates divided into two groups: betamethasone group, whose mothers received betamethasone 12 mg two times 24 h apart, and no betamethasone group, whose mothers did not receive any steroid agent during the antenatal period. Serum 17-hydroxyprogesterone (17-OHP) levels and cortisol levels were measured during the first six hours of life. In addition, adrenal gland length and width were determined on the first day of life. Hormone tests and ultrasonographic evaluation were repeated on the fifth day of life. Results: We found statistically significant reductions in 17-OHP and cortisol levels at birth in corticosteroid-exposed neonates (p <0.05). There was no significant difference between the study groups with regard to adrenal gland length and width (p >0.05). Conclusions: This study demonstrates that betamethasone use in preterm neonates reduces endogenous 17-OHP and cortisol levels; however, it has no effect on adrenal gland size.en_US
dc.identifier.endpage1031en_US
dc.identifier.issn0334-018X
dc.identifier.issue11en_US
dc.identifier.pmid20101888en_US
dc.identifier.scopus2-s2.0-75749098920en_US
dc.identifier.scopusqualityQ2
dc.identifier.startpage1027en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12418/10029
dc.identifier.volume22en_US
dc.identifier.wosWOS:000273080400006en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFREUND PUBLISHING HOUSE LTDen_US
dc.relation.ispartofJOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISMen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectadrenal glanden_US
dc.subjectcortisolen_US
dc.subject17-hydroxyprogesteroneen_US
dc.subjectnewbornen_US
dc.titleEffect of Antenatal Betamethasone Use on Adrenal Gland Size and Endogenous Cortisol and 17-Hydroxyprogesterone in Preterm Neonatesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu